As one of the key disciplines of the Ministry of Education and one of the key clinical specialties of the Ministry of Health, the Department is the largest comprehensive treatment center of abdominal tumor in China with a medical team of 9 professors, 5 associate professors, 12 attending doctors, over 30 residents and postgraduates in oncology and 48 nurses.
The Department owns 140 beds in the Main Capmus and 40 in Shangjin Branch Campus. The Department is mainly engaged in the comprehensive treatment of chemotherapy, radiotherapy, interventional therapy, targeting therapy and immunotherapy of abdominal tumors, including alimentary tract tumors (gastric cancer, intestinal cancer, liver cancer, pancreatic cancer, biliary tract tumor, etc.), genitourinary system tumors (renal carcinoma, bladder cancer, ureter carcinoma, prostate cancer, testicular tumor, etc.), gynecologic tumors (ovarian cancer, cervical cancer, endometrial cancer, germ cell tumor), etc. It covers subspecialties, including gastric cancer, pancreatic cancer, liver cancer, colorectal cancer, neuroendocrine tumor, genitourinary system tumor, biliary tract tumor, integration of TCM and Western medicine, interventional therapy, etc.
The Department attaches great attention to the multidisciplinary comprehensive treatment, and the individualized treatment model to develop the best individual treatment plan for patients under the guidance of their biomarkers. In 2008, China’s first Association for Molecular Targeted Therapy of Oncology was established by Professor Bi Feng, who has been a national leader in this field and the chairman of the Association (one session per year) for ten years, editing some journals, such as Times of Molecular Targeted Therapy of Oncology.
Clinical Trial Base: The Department, the clinical trial base of new anti-tumor drugs designated by the State, provides the patients with the latest research outcomes; it has undertaken and finished over 80 clinical trials of new drugs and new treatments at home and abroad. As the leader in many nationwide multicenter clinical trials of new drugs, such as Dolafenib, Matatinib, Cabazitaxel, etc., the Department makes it possible for the inpatients to get the latest antineoplastic therapy in line with that of the developed countries in Europe and the United States.
Medical Features: (1) combination of normativity and individuation; (2) molecular-targeted therapy of oncology with international synchronization; (3) powerful radiotherapy platform and team; (4) excellent interventional diagnosis & treatment; (5) clinical trial base of new anti-tumor drugs with international synchronization; (6) specialists for multidisciplinary diagnosis and treatment.
The Department, with 4 Ph.D. tutors and 9 master tutors, undertakes major scientific research projects such as National Science Fund for Distinguished Young Scholars and Ministry of Science and Technology of China, a number of projects of National Natural Science Fund of China and the projects of the scientific research funds of Sichuan Province and other ministries. In West China Hospital Science Park of Sichuan University, the Department owns a research base of molecular-targeted therapy of oncology, with world-class laboratory equipment and functional units, including a molecular biology laboratory, a signal molecule laboratory, a few cell culture labs, an immunohistochemical lab, an electrophoretic lab, a disinfecting supply room, and an academic conference room, etc.
